November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Cosmeceutical market expanding rapidly while scientific support lags
June 1st 2004Washington - Dermatologists need to keep cosmeceuticals under the magnifying glass and identify the science supporting their efficacy so that they can better advise patients about over-the-counter skincare, said Patricia Farris, M.D., at the annual meeting of the American Academy of Dermatology.
Off-label uses broaden as derms explore Botox
June 1st 2004Washington - The number of potential dermatologic uses for botulinum toxin type A (Botox Cosmetic) continues to increase, but the already sizable list probably only represents the tip of the iceberg, says Seth L. Matarasso, M.D., at the annual meeting of the American Academy of Dermatology
Botox applications continue to expand
May 1st 2004Maui, Hawaii - Next-generation botulinum toxin treatments promise to improve problems ranging from smokers' lines to sweaty palms. However, such treatments aren't for novices - be they dermatologists or patients. "As Botox is now becoming more widely accepted and we're becoming more used to its application, we're finding new uses for it," said Kevin S. Pinski, M.D.
FDA gives nod; Hylaform joins ranks of fillers
May 1st 2004Santa Barbara, Calif. -- The U.S. Food and Drug Administration late last month granted approval for Inamed Corp.'s Hylaform (Hylan-B gel). The hyaluronic-acid-based dermal filler is indicated for injection into the deep dermis for correction of moderate-to-severe facial wrinkles and folds. The move, while expected, adds a few wrinkles of its own to the growing U.S. market for dermal fillers.
Botox has long duration of action for Tx of axillary hyperhidrosis
May 1st 2004Washington - Intradermal botulinum toxin type A (Botox) for the treatment of primary axillary hyperhidrosis produces a durable effect, with nearly half of patients requiring only one treatment over a one-year period, according to study data released at the annual meeting of the American Academy of Dermatology here.
Lasers target most pigmented lesions
May 1st 2004Washington - A number of different lasers covering a wide range of wavelengths can be used to treat a variety of pigmented lesions, but certain lasers work better than others and similarly, response varies by lesion type, said Jeffrey S. Dover, M.D., at the annual meeting of the American Academy of Dermatology here.
Inexpensive methods of sun protection
May 1st 2004Washington - Photoprotection has an important place in the prevention of skin cancer, but it should involve a multifactorial approach that puts inexpensive natural protection first, said Robin Marks, M.B.B.S, at the annual meeting of the American Academy of Dermatology.
Oral tazarotene shows sustained efficacy in psoriasis
May 1st 2004Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.